Search

everythinglearnresearchcommunity

for

Search:↓

The combination treatment showed a higher response rate but no significant survival benefits.

The drug combination was safe and showed promise in treating advanced tumors.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Upadacitinib effectively treats severe alopecia areata and is safe.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Ritlecitinib is safe and may effectively treat alopecia areata.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.

The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

The botanical treatment for hair loss shows promise, especially for children.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.